Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 07, 2023 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results

- Transformational progress in 2022 marked by reprioritization of high-value neurology pipeline and validation of TRACER™ novel capsid platform through transactions with Pfizer and Novartis - -...
March 06, 2023 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets

Options exercised on two targets; Voyager eligible to receive associated development, regulatory, and commercial milestones, plus tiered royalties With option exercise, potential to expand agreement...
February 28, 2023 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
February 09, 2023 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
January 24, 2023 16:01 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has...
January 09, 2023 07:00 ET | Source: Voyager Therapeutics, Inc.

Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases

- Voyager to receive up-front consideration of $175 million including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial...
January 04, 2023 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
December 14, 2022 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors

CAMBRIDGE, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
November 29, 2022 16:01 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has...
November 08, 2022 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results

- Voyager’s TRACERTM capsid platform validated by Pfizer option exercise - - Data characterizing a novel receptor and demonstrating low-dose potential further validate TRACER - - Pipeline programs...